Valuation: Kopran Limited

Market Cap 9.49B 99.19M 84.97M 79.5M 72.77M 137M 138M 939M 366M 4.77B 372M 364M 15.77B P/E 2025
21.9x
P/E 2026 20.2x
Enterprise Value 11.01B 115M 98.58M 92.24M 84.43M 158M 161M 1.09B 425M 5.53B 432M 423M 18.29B EV / Sales 2025
1.55x
EV / Sales 2026 0.99x
Free-Float
49.79%
Yield 2025
1.71%
Yield 2026 2.78%
1 day-1.82%
1 week+3.10%
Current month+2.65%
1 month-3.88%
3 months+17.24%
6 months+50.86%
Current year+30.35%
1 week 192.05
Extreme 192.05
211
1 month 166
Extreme 166
211
Current year 107
Extreme 107
219
1 year 107
Extreme 107
219
3 years 107
Extreme 107
369.7
5 years 96
Extreme 96
370.45
10 years 15.1
Extreme 15.1
370.45
Manager TitleAgeSince
Chief Executive Officer 71 1997-06-10
Director of Finance/CFO - 2014-09-28
Chief Tech/Sci/R&D Officer - 2026-06-25
Director TitleAgeSince
Director/Board Member 71 1977-06-10
Chairman 84 2010-01-03
Director/Board Member 43 2018-05-28
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%+3.10% - - 99.19M
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +0.98%+4.97%+31.31%+53.20% 422.21B
Weighted average by Cap. +1.14%+5.09%+44.31%+72.55%

Financials

2025 2026
Net sales 6.3B 65.8M 56.37M 52.74M 48.28M 90.61M 91.8M 623M 243M 3.16B 247M 242M 10.46B 6.81B 71.22M 61.01M 57.08M 52.25M 98.06M 99.36M 674M 263M 3.42B 267M 262M 11.32B
Net income 386M 4.03M 3.45M 3.23M 2.96M 5.55M 5.62M 38.16M 14.88M 194M 15.13M 14.8M 641M 257M 2.69M 2.3M 2.16M 1.97M 3.7M 3.75M 25.47M 9.93M 129M 10.1M 9.88M 428M
Net Debt 1.28B 13.41M 11.49M 10.75M 9.84M 18.47M 18.71M 127M 49.52M 645M 50.36M 49.26M 2.13B 1.52B 15.89M 13.61M 12.73M 11.66M 21.88M 22.16M 150M 58.67M 764M 59.66M 58.36M 2.53B
Logo Kopran Limited
Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.
Employees
1,156
Date Price Change Volume
26-08-21 ₹196.09 -1.82% 75,827
26-08-20 ₹199.72 -3.73% 113,587
26-08-19 ₹207.46 +2.95% 275,598
26-08-18 ₹201.51 +0.90% 220,320
26-08-17 ₹199.71 +5.00% 183,408